<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01449916</url>
  </required_header>
  <id_info>
    <org_study_id>SSSP</org_study_id>
    <secondary_id>R24TW007988</secondary_id>
    <nct_id>NCT01449916</nct_id>
  </id_info>
  <brief_title>Simplified Severe Sepsis Protocol in Zambia</brief_title>
  <acronym>SSSP</acronym>
  <official_title>Improving Sepsis Diagnosis and Treatment: Simplified Severe Sepsis Protocol (SSSP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fogarty International Center of the National Institute of Health</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized control trial assessing the impact of a simple evidence-based&#xD;
      protocol for the treatment severe sepsis in Zambia. The intervention protocol consists of a&#xD;
      scheduled fluid regimen, early blood culture and antibiotics, and dopamine and blood&#xD;
      transfusion when necessary. It is hypothesized that the protocol will significantly decrease&#xD;
      in-hospital mortality in patients with severe sepsis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In recent years, evidence-based protocols of bundled therapies have improved survival of&#xD;
      severe sepsis in developed countries. However, in sub-Saharan Africa, simple therapies such&#xD;
      as IV fluids and early antibiotics are frequently under-utilized. Furthermore, although&#xD;
      tuberculosis is a common cause of severe sepsis in the region, accurate and timely diagnosis&#xD;
      of tuberculosis-associated severe sepsis remains elusive.&#xD;
&#xD;
      The aims of this study are (1) To assess the impact on survival of a simple evidence-based&#xD;
      protocol for severe sepsis, (2) To evaluate the cost of implementation for a simplified&#xD;
      severe sepsis protocol (3) To develop a clinical diagnostic score for identifying&#xD;
      tuberculosis in HIV positive patients with severe sepsis (4) To assess the performance of the&#xD;
      Xpert TB/RIF rapid PCR system for diagnosing tuberculosis in HIV positive patients with&#xD;
      severe sepsis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    High mortality rate in intervention arm for patients with RR &gt;40 AND SpO2 &lt; 90%.&#xD;
  </why_stopped>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-hospital all cause mortality</measure>
    <time_frame>During hospitalization, expected average 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>28-day all-cause mortality</measure>
    <time_frame>28-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital all cause mortality adjusted for illness severity</measure>
    <time_frame>During hospitalization, expected average 14 days</time_frame>
    <description>Adjusted for SAPS3 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day all cause mortality adjusted for baseline illness severity</measure>
    <time_frame>28-day</time_frame>
    <description>Adjusted for SAPS3 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative adverse events</measure>
    <time_frame>During hospitalization, expected average 14 days</time_frame>
    <description>A composite outcome consisting of dopamine extravasation, dopamine-associated tissue ischemia or necrosis, iatrogenic pulmonary oedema, and transfusion-related adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment cost per patient</measure>
    <time_frame>During hospitalization, expected average 14 days</time_frame>
    <description>A budget impact analysis will determine the cost of treatment per patient using a mix of direct measurements and micro-cost observation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic changed due to culture results</measure>
    <time_frame>During hospitalization, expected average 14 days</time_frame>
    <description>The proportion of patients whose antibiotic regimen was changed due to information obtained from blood culture results.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Sepsis</condition>
  <condition>Severe Sepsis</condition>
  <arm_group>
    <arm_group_label>Simplified Severe Sepsis Protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This protocol consists of an early aggressive fluid strategy, early blood cultures and antibiotics, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Early blood cultures and antibiotics. Monitoring by study nurses as in experimental arm. Other interventions are according to admitting (non-study) doctors' orders.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Simplified Severe Sepsis Protocol</intervention_name>
    <description>Early fluid protocol, early blood cultures and antibiotics; blood cultures and titrated dopamine in selected patients; monitoring based on vital signs and physical examination</description>
    <arm_group_label>Simplified Severe Sepsis Protocol</arm_group_label>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Suspected infection&#xD;
&#xD;
          -  2 or more of SIRS criteria:&#xD;
&#xD;
               -  Heart rate &gt;90/min&#xD;
&#xD;
               -  Respiratory rate &gt;20/min&#xD;
&#xD;
               -  Temperature &gt;= 38° C or &lt;= 36° C&#xD;
&#xD;
               -  White blood count &gt; 12,000 or &lt; 4,000/µL&#xD;
&#xD;
          -  1 or more of the following signs of end-organ dysfunction&#xD;
&#xD;
               -  Systolic blood pressure &lt; 90 mm Hg&#xD;
&#xD;
               -  Mean arterial blood pressure (MAP) &lt; 65 mm Hg&#xD;
&#xD;
               -  Confusion/altered mentation&#xD;
&#xD;
               -  Urine output &lt; 0.5 mL/kg/hr&#xD;
&#xD;
               -  Creatinine increase &gt; 0.5 mg/dL&#xD;
&#xD;
               -  Creatinine &gt; 0.5 mg/dL above upper limit of normal&#xD;
&#xD;
               -  Platelet &lt; 100x109/L&#xD;
&#xD;
               -  Respiratory rate &gt; 40/min&#xD;
&#xD;
               -  Jaundice&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  GI bleed&#xD;
&#xD;
          -  Need for urgent surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin L Andrews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University and University of Zambia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Teaching Hospital</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Zambia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 5, 2011</study_first_submitted>
  <study_first_submitted_qc>October 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2011</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Severe Sepsis</keyword>
  <keyword>Protocol</keyword>
  <keyword>Zambia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

